Preclinical Screening Platform Identifies Azatadine‐Dimaleate as a Potent Repurposed Therapeutic Against SARS‐CoV‐2 Infection
Journal of Medical Virology · 2025
DOI: 10.1002/jmv.70713 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Ahlam Ali und 13 weiteren Autor:innen. Beteiligte Einrichtung: Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast; Belfast, Belfast, I…. Hauptthemen laut MEDLINE: SARS-CoV-2, Drug Repositioning, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Research and Innovation (UKRI) rapid response call MC_PC_19057 (UP, AA, KM); HSC R&D Division Opportunity-led Research Award COM/5613/20 (UP); Medical Resea….
Abstract (Originalsprache)
The emergence of SARS‐CoV‐2 posed a major global public health threat, necessitating urgent development of therapeutics. Despite vaccine availability, continuous emergence of viral variants with enhanced transmissibility and immune escape capabilities, and consequential impacts on health services, requires effective antiviral therapeutics. Drug repurposing offers an expeditious strategy to identify therapeutics with established safety profiles. We implemented a comprehensive three‐tiered validation approach, screening 2,570 compounds against SARS‐CoV‐2 in vitro, followed by ex vivo validation in well‐differentiated primary human bronchial epithelial cell (WD‐PBEC) cultures, and rigorous in vivo assessment. This methodical progression identified Azatadine‐Dimaleate, a H1‐receptor antagonist, as an exceptional candidate with consistent efficacy across all systems. Azatadine‐Dimaleate demonstrated potent antiviral activity‐ EC50: 4.0 µM (95% CI: 3.2–4.8 µM), reducing viral replication by ~5,000‐fold at 25 µM in epithelial cultures and lowering peak viral titers in WD‐PBECs by 1.4 log 10 , and 2.33 log 10 at 48 and 96 hpi, respectively, compared to controls. There was also a concomitant reduction in expression of interferons and pro‐inflammatory genes, including IL‐6. Combination with Remdesivir synergistically enhanced antiviral activity, reducing the EC50 of both drugs by > 60%. In the K18‐hACE2 transgenic mouse model, Azatadine‐Dimaleate significantly reduced weight loss (4% vs. 12%, p ≤ 0.05), decreased viral loads, and halved viral antigen expression in lung tissues. Unlike many candidates that faltered in complex models, Azatadine‐Dimaleate maintained efficacy across all platforms. These findings support its clinical evaluation, alone or in combination with Remdesivir, as a versatile therapeutic with strong potential to address current and emerging SARS‐CoV‐2 variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast; Belfast, Belfast, Ireland.
- Current Affiliation: School of Life Sciences, University of Wolverhampton, Wolverhampton, UK.
- Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast; Belfast, Belfast, Ireland.
- Department of Infection Biology and Microbiomes, University of Liverpool, Liverpool, UK.
- Regional Virology Laboratory, Belfast Trust, Belfast, Ireland.
- Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Förderung
- UK Research and Innovation (UKRI) rapid response call MC_PC_19057 (UP, AA, KM); HSC R&D Division Opportunity-led Research Award COM/5613/20 (UP); Medical Resea…
Zitieren
APA
Ali, A., Courtney, D., Broadbent, L., Sharma, P., Bamford, C. G. G., Manzoor, S., Touzelet, O., McCaughey, C., Kirby, A., Bentley, E., Kipar, A., Mills, K. I., Stewart, J. P., & Power, U. F. (2025). Preclinical Screening Platform Identifies Azatadine‐Dimaleate as a Potent Repurposed Therapeutic Against SARS‐CoV‐2 Infection. Journal of Medical Virology. https://doi.org/10.1002/jmv.70713
Vancouver
Ali A, Courtney D, Broadbent L, Sharma P, Bamford CGG, Manzoor S, et al. Preclinical Screening Platform Identifies Azatadine‐Dimaleate as a Potent Repurposed Therapeutic Against SARS‐CoV‐2 Infection. Journal of Medical Virology. 2025. doi:10.1002/jmv.70713
BibTeX
@article{Ali2025,
author = {Ali, Ahlam and Courtney, David and Broadbent, Lindsay and Sharma, Parul and Bamford, Connor G G and Manzoor, Sheerien and Touzelet, Olivier and McCaughey, Conall and Kirby, Adam and Bentley, Eleanor and Kipar, Anja and Mills, Ken I and Stewart, James P and Power, Ultan F},
title = {Preclinical Screening Platform Identifies Azatadine‐Dimaleate as a Potent Repurposed Therapeutic Against SARS‐CoV‐2 Infection},
journal = {Journal of Medical Virology},
year = {2025},
doi = {10.1002/jmv.70713}
}
EUVIMED